Astra, Merck’s Lynparza Approved in U.S. as Adjuvant Treatment

AstraZeneca and Merck’s Lynparza (olaparib) received FDA approval for adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

NOTE

• AstraZeneca Plc rose 0.6% to GBp9,275.00 as of last close
  • The average 12-month price target of GBp10,175.00 is 9.7% above the current price
  • 29 buys, 4 holds, 1 sells

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used with permission.